- Home
- EDUC vs VYNE Comparison
EDUC vs VYNE Comparison
Compare EDUC & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDUC | VYNE |
|---|---|---|
| Founded | 1965 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 12.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | EDUC | VYNE |
|---|---|---|
| Price | $1.28 | $0.38 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 43.4K | ★ 1.0M |
| Earning Date | 01-12-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,415,900.00 | $524,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.29 |
| 52 Week Low | $0.92 | $0.28 |
| 52 Week High | $1.95 | $4.30 |
Technical Indicators
Market Signals| Indicator | EDUC | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 46.45 | 50.93 |
| Support Level | $1.21 | $0.35 |
| Resistance Level | $1.35 | $0.40 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 57.87 | 48.28 |
Price Performance
Historical ComparisonAbout EDUC Educational Development Corporation
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.